MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Gesloten

SectorGezondheidszorg

2.95 2.43

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.91

Max

2.95

Belangrijke statistieken

By Trading Economics

Inkomsten

-15M

-40M

Verkoop

8.2M

50M

Winstmarge

-80.43

Werknemers

435

EBITDA

-19M

-42M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+39.37% upside

Dividenden

By Dow Jones

Volgende Winsten

11 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-62M

1.1B

Vorige openingsprijs

0.52

Vorige sluitingsprijs

2.95

Nieuwssentiment

By Acuity

50%

50%

166 / 349 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 apr 2026, 04:27 UTC

Belangrijke Nieuwsgebeurtenissen

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

3 apr 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

3 apr 2026, 18:30 UTC

Belangrijke Nieuwsgebeurtenissen

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3 apr 2026, 18:14 UTC

Marktinformatie

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3 apr 2026, 17:50 UTC

Marktinformatie

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3 apr 2026, 17:44 UTC

Acquisities, Fusies, Overnames

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3 apr 2026, 16:50 UTC

Belangrijke Nieuwsgebeurtenissen

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3 apr 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

3 apr 2026, 16:12 UTC

Winsten

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3 apr 2026, 15:56 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3 apr 2026, 15:56 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Global Equities Roundup: Market Talk

3 apr 2026, 15:56 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Global Forex and Fixed Income Roundup: Market Talk

3 apr 2026, 15:20 UTC

Belangrijke Nieuwsgebeurtenissen

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3 apr 2026, 15:08 UTC

Acquisities, Fusies, Overnames

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3 apr 2026, 14:11 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3 apr 2026, 12:56 UTC

Marktinformatie

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3 apr 2026, 08:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

3 apr 2026, 08:01 UTC

Marktinformatie

Global Equities Roundup: Market Talk

3 apr 2026, 08:01 UTC

Marktinformatie

Meituan's Profitability Likely to Improve This Year -- Market Talk

3 apr 2026, 07:45 UTC

Marktinformatie

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3 apr 2026, 06:17 UTC

Marktinformatie

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3 apr 2026, 06:17 UTC

Marktinformatie

Global Equities Roundup: Market Talk

3 apr 2026, 04:33 UTC

Marktinformatie

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3 apr 2026, 04:33 UTC

Marktinformatie

Global Equities Roundup: Market Talk

3 apr 2026, 04:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

3 apr 2026, 04:01 UTC

Marktinformatie

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

3 apr 2026, 02:01 UTC

Marktinformatie

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

3 apr 2026, 01:59 UTC

Marktinformatie

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

3 apr 2026, 01:44 UTC

Marktinformatie

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

3 apr 2026, 01:22 UTC

Marktinformatie

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Peer Vergelijking

Prijswijziging

Maravai LifeSciences Holdings Inc (Class A) Prognose

Koersdoel

By TipRanks

39.37% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4 USD  39.37%

Hoogste 5 USD

Laagste 3 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Maravai LifeSciences Holdings Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

3

Buy

3

Hold

0

Sell

Technische score

By Trading Central

2.02 / 2.115Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

166 / 349 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat